Cargando…
Evaluation of the antitumor activity of NOV202, a novel microtubule targeting and vascular disrupting agent
PURPOSE: Overall, ~65% of patients diagnosed with advanced ovarian cancer (OC) will relapse after primary surgery and adjuvant first-line platinum- and taxane-based chemotherapy. Significant improvements in the treatment of OC are expected from the development of novel compounds having combined cyto...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5417661/ https://www.ncbi.nlm.nih.gov/pubmed/28496304 http://dx.doi.org/10.2147/DDDT.S133189 |